Every Form 4 that Charles River Laboratories International, Inc. (CRL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CRL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRL filings page.
Shannon M. Parisotto, CEVP, Disc & Safety Assessment at Charles River Laboratories International, Inc., exercised options to acquire 981 common shares at $208.44 per share and sold 981 shares at $308.44 per share on October 5, 2026. The exercise and sale occurred under a Rule 10b5-1 Trading Plan adopted March 4, 2026. After the exercise, 2,944 stock options remained. Reported indirect holdings included 9,680 common shares held by Trust and 28,510 common shares held by Karpathos Investments LLC.
Charles River Laboratories International, Inc. EVP & Chief Financial Officer Glenn Coleman purchased 10 shares of common stock at $297.43 per share on September 30, 2026, through the Company's Employee Stock Purchase Plan at fair market value on the purchase date. He held 27,762 shares directly following the purchase. Coleman elected to participate during an open trading window before the quarterly purchase period began; no Rule 10b5-1 plan is reported.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) director James C. Foster reported an option exercise-and-sale transaction in the company’s common stock. On August 25, 2026, he exercised stock options covering 33,561 shares of common stock at exercise prices of $194.12 and $208.44 per share, receiving the underlying shares.
On the same date, he sold 33,561 shares of common stock at $300.00 per share in an open market or private transaction. According to the filing, this exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 6, 2026. Following these transactions, Foster also reports indirect holdings of common stock through several trusts and Grantor Retained Annuity Trusts.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported an insider equity transfer by Chief Executive Officer and director Birgit Girshick. On 2026-08-19, Girshick made a bona fide gift of 528 shares of Common Stock, leaving 35,485 shares held directly and 43,803 shares held indirectly through a revocable trust.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) executive Shannon M. Parisotto, CEVP, Discovery & Safety Assessment, reported an option exercise-and-sale transaction. Parisotto exercised 2,039 stock options at an exercise price of $194.12 per share, acquiring 2,039 common shares, and then sold 2,039 common shares at $294.12 per share. The sale was made pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following these transactions, Parisotto reports indirect ownership of 9,680 common shares by a trust and 28,510 common shares through Karpathos Investments LLC, as shown in the holding entries.
For CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL), director Nancy C. Andrews reported an option exercise and same-day sale. She exercised 573 stock options at an exercise price of $164.30 per share, acquiring 573 shares of common stock, and then sold 573 common shares at $285.24 per share. After these transactions, she reported 3,964 common shares held indirectly by trust. The Rule 10b5-1 trading-plan box was not checked.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Chief Executive Officer Birgit Girshick exercised stock options for 6,500 shares of common stock on August 11, 2026 at an exercise price of $179.66 per share. The resulting 6,500 common shares were then sold at $279.90 per share on the same date, in a transaction marked as a sale. The company reports that this exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 3, 2025. Following these transactions, Girshick has an indirect holding of 43,803 common shares through a revocable trust.
Charles River Laboratories International executive Shannon M. Parisotto, CEVP, Discovery & Safety Assessment, exercised stock options for 3,714 shares of common stock at an exercise price of $179.66 per share on 2026-08-11 and sold the same 3,714 shares at $279.66 per share. The exercise and sale were carried out pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following these transactions, reported indirect holdings include 9,680 shares held by a trust and 28,510 shares held by Karpathos Investments LLC.
Charles River Laboratories International, Inc. executive Joseph W. LaPlume, EVP, Corp Strategy & Develop, reported a bona fide gift of 257 shares of common stock on 2026-08-10. The transaction was a disposition made at a reported per-share price of $0.00, leaving him with 31,041 shares of direct ownership afterward.
Charles River Laboratories International director James C. Foster exercised stock options for 28,733 shares of common stock at an exercise price of $179.66 per share on August 10, 2026 and immediately sold 28,733 shares at $275.00 per share. The options, originally exercisable from May 29, 2021 and expiring May 29, 2030, now show 0 derivative shares remaining from this grant. The exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 6, 2026. Following these transactions, Foster is reported with indirect holdings of common stock through various trusts and GRATs, including 5,423 shares in a 2024 GRAT, 10,780 shares in a 2025 GRAT, and 20,000 shares in a 2026 GRAT.
Charles River Laboratories International, Inc. senior vice president of finance and chief accounting officer Michael Gunnar Knell reported option exercises and share sales on 2026-08-06. He exercised stock options covering 2,345 shares of common stock at strike prices of $179.66, $194.12, and $208.44 per share and reported open-market sales totaling 6,645 shares of common stock at prices between $258.53 and $265.17 per share, executed in multiple trades at weighted average prices for several tranches.
Charles River Laboratories International, Inc. reported that EVP & Chief People Officer Victoria L. Creamer exercised stock options for 4,179 shares of common stock on 2026-08-06 at an exercise price of $179.66 per share and immediately sold 4,179 shares of common stock at $259.16 per share. The exercised options covered 4,179 shares and now show 0 derivative shares remaining from this grant.
Charles River Laboratories International, Inc. executive Shannon M. Parisotto, CEVP of Discovery & Safety Assessment, reported a sale of 5,046 shares of common stock at $263.00 per share on August 5, 2026, under a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following the sale, Parisotto directly holds 4,807 shares, and also reports indirect ownership of 9,680 shares held by a trust and 28,510 shares held through Karpathos Investments LLC.
Charles River Laboratories director James C. Foster reported an open-market sale of 75,000 shares of common stock at $225.00 per share. The sale was executed pursuant to a Rule 10b5-1 Trading Plan adopted on March 6, 2026. After the sale, he holds 31,596 shares directly and additional indirect holdings through various trusts and GRATs.
Charles River Laboratories director James C. Foster reported exempt, bona fide gifts and related trust transfers of 366,722 shares of common stock dated 2026-06-05. The Form 4 shows these shares moving among his direct holdings, revocable trusts he controls, and trusts associated with his spouse, all at a stated price of $0.00 per share, indicating no sale proceeds. Following these transactions, Foster holds 106,596 shares directly and 155,611 shares indirectly through a trust, plus additional indirect positions of 20,000 shares in a 2026 GRAT, 10,780 shares in a 2025 GRAT, 5,423 shares in a 2024 GRAT, and 10,000 shares in a trust held by his spouse.
Charles River Laboratories' CEO Birgit Girshick reported exempt insider transfers primarily structured as gifts rather than market sales. She made bona fide gifts totaling 6,772 shares of Common Stock on June 5, 2026, including a transfer of 3,386 shares to a revocable trust she controls under Rule 16a-13.
Following these transfers, she holds 36,013 Common shares directly and 43,803 shares indirectly through the revocable trust. She also holds stock options covering 8,722 shares of Common Stock, exercisable at $208.44 per share and expiring on May 31, 2034. These transactions did not involve any sale proceeds.
Charles River Laboratories executive Shannon M. Parisotto, Chief Executive Vice President for Discovery & Safety Assessment, reported non-market movements in Common Stock. On June 5, 2026, she made bona fide gifts totaling 3,058 shares, with 1,529 shares transferred as an exempt move under Rule 16a-13 to a revocable trust she controls.
After these transactions, she holds 9,853 Common Stock shares directly, 9,680 shares indirectly through a trust, and 28,510 shares indirectly via Karpathos Investments LLC. All reported actions are gifts or internal reallocations, not open-market purchases or sales.
Barg Steven reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories director Steven Barg received an equity grant as part of his board compensation. He was awarded 422 shares of Common Stock in the form of restricted stock units at a reference price of $174.79 per share, bringing his direct holdings to 3,287 shares following the grant.
The grant was made in lieu of director service fees for the term beginning on May 5, 2026. These restricted stock units will vest on the earlier of June 2, 2027 or the business day before the company’s next annual meeting of shareholders, making this a routine, compensation-related, non-market transaction.
Coleman Glenn reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories International EVP & CFO Glenn Coleman received a stock grant. On May 29, he was awarded 6,640 shares of common stock at a reference value of $180.71 per share as compensation, increasing his directly held stake to 27,752 shares.
A footnote explains that the unvested restricted stock units underlying this award will vest in equal annual installments on May 29, 2027, May 29, 2028, May 29, 2029, and May 29, 2030, subject to the applicable award terms.
Charles River Laboratories International EVP and Chief Information Officer Mark Mintz received an equity award of 2,534 shares of common stock at a reference price of $180.71 per share. To cover tax obligations, 305 shares on May 30, 2026 and 64 shares on May 31, 2026 were withheld as tax-withholding dispositions, not open-market sales. After these transactions, he directly held 9,546 shares. The related restricted stock units are scheduled to vest annually on May 29 of 2027, 2028, 2029, and 2030.
Charles River Laboratories executive Joseph W. LaPlume reported equity compensation activity involving company common stock. On May 29, he received a grant of 5,257 shares of Common Stock, increasing his direct holdings. The filing shows this as a grant or award, not an open-market purchase.
On May 30 and May 31, a total of 979 shares were disposed of at $180.71 per share to satisfy tax withholding obligations related to the award. These tax-withholding dispositions are not open-market sales. After these transactions, LaPlume directly holds 31,298 shares of Common Stock.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. executive Michael Gunnar Knell, SVP Finance and CAO, reported compensation-related equity activity in company common stock. On May 29, 2026, he received a grant of 1,837 shares of common stock valued at $180.71 per share as a stock award. On May 30, 2026 and May 31, 2026, a total of 200 shares (152 and 48 shares, respectively) were disposed of as tax-withholding transactions at the same reference price of $180.71 per share, meaning the shares were used to cover tax obligations rather than sold in the open market. After these transactions, Knell directly owned 16,152 shares of common stock. A footnote states that unvested restricted stock units will ratably vest each year on May 29, 2027, May 29, 2028, May 29, 2029, and May 29, 2030, indicating a multi-year vesting schedule for his equity awards.
Charles River Laboratories International Chief Executive Officer Birgit Girshick reported equity compensation and related tax withholding transactions. On May 29, 2026, she received a grant of 9,961 shares of common stock at $180.71 per share. On May 30–31, 2026, a total of 1,582 shares were disposed of as tax-withholding transactions at the same price. After these transactions, she directly owned 39,399 shares and indirectly held 40,417 shares through a revocable trust. A footnote states that unvested restricted stock units vest annually on May 29, 2027, 2028, 2029, and 2030.
Charles River Laboratories International director James C. Foster reported a set of equity holdings and one tax-related share disposition in company common stock. The filing shows 1,596 shares of common stock were disposed of at $180.71 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in the open market.
After this transaction, Foster directly holds 279,957 shares of common stock. The filing also lists several indirect holdings, including shares held by a spouse, by trusts, and by 2024 and 2025 GRAT vehicles. Overall, the activity appears routine and primarily administrative, focused on updating ownership records and satisfying tax requirements tied to equity compensation.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. executive Victoria L. Creamer, EVP & Chief People Officer, received a grant of 5,135 shares of common stock at $180.71 per share. To cover tax liabilities, 810 shares were disposed of through tax-withholding transactions over two days. Following these compensation-related entries, she directly holds 30,051 common shares.
Charles River Laboratories International, Inc. executive Shannon M. Parisotto reported routine equity compensation activity and related tax withholding. On May 29, 2026, she received a grant of 4,361 shares of Common Stock at $180.71 per share as a compensation award. A footnote states that the underlying unvested restricted stock units vest annually on May 29, 2027, 2028, 2029, and 2030.
To cover tax obligations, a total of 721 shares of Common Stock were disposed of through tax-withholding transactions on May 30 and May 31, 2026, each at $180.71 per share. Following these transactions, she directly holds 11,382 shares of Common Stock. As of May 29, 2026, she also has indirect holdings of 28,510 shares through Karpathos Investments LLC and 8,151 shares held by a trust.
Charles River Laboratories International EVP & Chief People Officer Victoria L. Creamer reported routine share dispositions related to tax withholding. On May 26 and 27, a total of 346 shares of common stock were withheld at prices of $160.30 and $156.73 per share. After these transactions, she directly holds 25,726 shares of common stock.
Charles River Laboratories executive Shannon M. Parisotto reported routine share dispositions tied to compensation and estate planning, not open‑market trading. On May 26 and 27, 2026, 273 shares of common stock were withheld at prices of $160.30 and $156.73 per share to cover tax obligations, leaving 7,742 shares held directly.
On February 6, 2026, 7,169 shares were transferred as a bona fide gift from Parisotto to a revocable trust controlled by her, and are now reported as indirectly owned. Separate from the trust, she also reports indirect ownership of 28,510 shares through Karpathos Investments LLC.
Charles River Laboratories International executive Mark Mintz reported small tax-related share dispositions. On May 26, 2026, 64 shares of Common Stock were withheld at $160.30 per share to cover tax obligations. On May 27, 2026, an additional 47 shares were withheld at $156.73 per share. These transactions were coded as tax-withholding dispositions, not open-market sales, and Mintz now directly holds 7,381 shares of Common Stock.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Chief Executive Officer Birgit Girshick reported routine share movements related mainly to taxes. On May 26 and 27, 2026, she had tax-withholding dispositions totaling 618 shares of common stock, with 376 shares at $160.30 and 242 shares at $156.73.
After these dispositions, she held 31,020 shares directly. A separate holding line shows an additional 40,417 common shares held indirectly through a revocable trust as of May 26, 2026. The filing reflects tax and ownership mechanics rather than open-market buying or selling.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. senior vice president of finance and chief accounting officer Michael Gunnar Knell reported two small tax-related share dispositions. On May 26, 2026, 50 shares of common stock were delivered at $160.30 per share, and on May 27, 2026, 37 shares were delivered at $156.73 per share. Both transactions are classified as tax-withholding dispositions to pay an exercise price or tax liability, rather than open-market sales. Following these transactions, Knell directly holds 14,515 shares of common stock.
Charles River Laboratories International EVP Joseph W. LaPlume reported routine tax-related share dispositions in company stock. On May 27, 185 shares of common stock were surrendered at $156.73 per share, and on May 26, 243 shares were surrendered at $160.30 per share.
Both transactions are coded as tax-withholding dispositions, meaning shares were delivered to cover exercise price or tax liabilities rather than sold in open-market trades. After these events, LaPlume directly holds 27,020 shares of Charles River Laboratories common stock.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. director Nancy C. Andrews reported non-market, bona fide gifts of common stock. On May 12, 2026, she disposed of a total of 7,928 shares through two gift transactions. One transfer of 3,964 shares was made to a revocable trust that she controls under Rule 16a-13, shifting those shares from direct to indirect ownership. Following these transactions, she held 1,438 shares directly and 3,964 shares indirectly through the trust, indicating a reallocation of her holdings rather than an open-market sale.
Barg Steven reported acquisition or exercise transactions in this Form 4 filing.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. director Steven Barg reported an equity award of 1,438 shares of Common Stock on May 8, 2026. The award is a grant, not an open-market purchase, with a reference price of $177.62 per share.
Following this grant, Barg directly holds 2,865 shares. According to the footnote, the unvested restricted stock units underlying this award will vest on the earlier of May 8, 2027 or the business day before the company’s next annual shareholder meeting.
Thompson Craig B. reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories International director Craig B. Thompson received a grant of 1,438 shares of Common Stock at $177.62 per share. This award is in the form of restricted stock units, increasing his directly held shares to 3,851.
The unvested restricted stock units vest on the earlier of May 8, 2027 or the business day before the company’s next annual meeting of shareholders, tying the award to continued service and the company’s governance calendar.
Charles River Laboratories International director Paul W. Graves received a stock award as part of his compensation. On the reported date, he acquired 1,438 shares of common stock at a value of $177.62 per share through a grant, not an open-market purchase. Following this award, his directly held stake increased to 2,384 shares. The underlying restricted stock units will vest on the earlier of May 8, 2027 or the business day before the company’s next annual meeting of shareholders.
Charles River Laboratories director Abraham Ceesay received a stock-based compensation award. On 5/8/2026, he acquired 1,438 shares of Common Stock at $177.62 per share as a grant or award, bringing his directly held stake to 2,384 shares. The related unvested restricted stock units vest on the earlier of May 8, 2027 or the business day prior to the company’s next annual meeting of shareholders, tying the award to continued service and future company performance rather than an open-market purchase.
MACKAY MARTIN reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories director Martin Mackay received equity grants of common stock as part of his board compensation. He was awarded 1,407 shares at a reference price of $177.62 per share and a separate award of 1,438 shares at the same price. One award was granted in lieu of director service fees for the term beginning May 5, 2026. The restricted stock units vest on the earlier of May 8, 2027 or the business day before the company’s next annual meeting of shareholders. Following these awards, one reported line shows Mackay holding 17,137 shares directly.
Andrews Nancy C reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories director Nancy C. Andrews received an equity grant of 1,438 shares of Common Stock, valued at $177.62 per share. This was a compensation-related grant, not an open-market purchase, and increased her direct holdings to 5,402 shares.
The footnote states that the unvested restricted stock units vest on the earlier of May 8, 2027, or the business day before the company’s next annual meeting of shareholders, tying the award to continued service and the company’s governance calendar.
Charles River Laboratories International director George Llado Sr. reported receiving equity-based compensation in the form of common stock awards. On May 8, 2026, he acquired 450 shares and a separate award of 1,438 shares, both at an indicated price of $177.62 per share.
Footnotes explain these are unvested restricted stock units that vest upon the earlier of May 8, 2027 or the business day prior to the company’s next annual meeting of shareholders. One grant was made in lieu of director service fees for the term commencing May 5, 2026.
Enyedy Mark J reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories director Mark J. Enyedy reported a stock award of 1,438 shares of Common Stock, valued at $177.62 per share. This was a compensation-related grant rather than an open-market purchase, bringing his direct holdings to 2,384 shares after the transaction.
The award consists of unvested restricted stock units that will vest upon the earlier of May 8, 2027, or the business day before the company’s next annual meeting of shareholders, aligning his compensation with long-term shareholder interests.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. director Reshema Kemps-Polanco reported receiving equity awards in the form of restricted stock units covering a total of 1,973 shares of Common Stock on May 8, 2026, valued at $177.62 per share.
The Form 4 shows one award for 535 shares and another for 1,438 shares, both characterized as grants or awards rather than open-market purchases. According to the footnotes, these unvested restricted stock units vest upon the earlier of May 8, 2027 or the business day prior to the company’s next annual meeting of shareholders.
One of the grants was made in lieu of director service fees for the term commencing May 5, 2026, meaning part of the director’s compensation is being paid in equity instead of cash. These are routine compensation-related acquisitions and not market trades.
Charles River Laboratories International director Virginia M. Wilson received an equity award. On 5/8/2026 she was granted 1,438 shares of Common Stock, valued at $177.62 per share, as a grant or award. After this acquisition, she directly holds 6,349 shares. According to the disclosure, these unvested restricted stock units will vest on the earlier of 5/8/2027 or the business day before the company’s next annual meeting of shareholders.
FOSTER JAMES C reported acquisition or exercise transactions in this Form 4 filing.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. director James C. Foster reported equity awards in the form of common stock tied to restricted stock units. On May 8, 2026, he received awards covering 422 shares and 1,438 shares of common stock at $177.62 per share.
These awards were granted in lieu of director service fees for the term commencing May 5, 2026. The unvested restricted stock units vest on the earlier of May 8, 2027 or the business day prior to the company’s next annual meeting of shareholders.
Following one of the reported awards, Foster is shown as directly holding 281,553 shares of common stock. Additional indirect holdings are reported through his spouse and various trusts, including GRAT structures, indicating a mix of direct and indirect ownership interests.
Coleman Glenn reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories International EVP & Chief Financial Officer Glenn Coleman received an equity grant of 21,112 shares of Common Stock on May 1, 2026. The grant was reported at $165.78 per share, and following this award he directly owns 21,112 shares.
According to the filing footnote, these unvested restricted stock units are scheduled to vest in equal annual installments on May 1, 2027, May 1, 2028, May 1, 2029, and May 1, 2030, tying the award to multi‑year service and performance with the company.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. executive Birgit Girshick, Corporate Executive VP & COO, reported an indirect bona fide gift of 328 shares of common stock on March 4, 2026. The gifted shares were held indirectly through a revocable trust and transferred at a reported price of $0.00 per share, reflecting a non-sale disposition.
After this gift, indirect holdings through the revocable trust were reported as 40,417 shares of common stock, while direct holdings were reported as 31,638 shares. A footnote explains that the indirect total includes shares previously reported as directly held, which are now correctly classified as indirectly held.
FOSTER JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories International Chairman, President and CEO James C. Foster received an equity award tied to the company’s common stock. He was granted 16,796 shares at a reference price of $178.61 per share, increasing his directly held stake to 279,693 shares.
According to a footnote, 100% of the unvested restricted stock units from this grant vest on March 2, 2028. Additional common stock is held indirectly through GRATs, trusts and a spouse account, and a separate footnote notes an exempt transfer of 9,220 shares from a 2025 GRAT account to direct holdings.
Charles River Laboratories International executive Joseph W. LaPlume bought 25 shares of common stock in an open-market purchase at $174.54 per share on March 3, 2026. Following this transaction, his directly held stake increased to 27,448 shares.
Charles River Laboratories International EVP Joseph W. LaPlume reported equity transactions in company stock. On January 30, 2026, he acquired 5,456 shares of common stock at $0 when performance share units granted on May 26, 2023 vested after meeting performance goals. On the same date, 1,749 shares were withheld and disposed of at $211.68 per share, typically reflecting taxes due on the vesting. After these transactions, he directly owned 27,423 shares of common stock.
Charles River Laboratories International executive Victoria L. Creamer reported stock transactions involving company common shares. On 01/30/2026, she acquired 5,006 shares of common stock at a price of $0, following the achievement of performance goals under performance share unit awards originally granted on May 26, 2023.
On the same date, she disposed of 1,296 common shares at a price of $211.68 per share. After these transactions, she directly owned 26,072 shares of Charles River Laboratories common stock in her capacity as EVP & Chief People Officer.